D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
In a recent transaction, Troy Wichterman, the Chief Financial Officer of BioLife Solutions Inc. (NASDAQ:BLFS), a company with a market capitalization of $1.05 billion and strong liquidity position according to InvestingPro analysis, sold 583 shares of the company’s common stock. The shares were sold at a price of $22.46 each, amounting to a total transaction value of $13,094. The transaction price was slightly above the current trading price of $21.87, with the stock showing notable volatility in recent months. Following this sale, Wichterman retains ownership of 187,727 shares in the company.
The sale was conducted under a pre-established Rule 10b5-1 trading plan, which was adopted by Wichterman to fulfill tax withholding obligations related to the vesting of restricted stock. With a current ratio of 4.73, the company maintains strong financial flexibility. Discover more comprehensive insider trading analysis and financial metrics with InvestingPro’s detailed research reports.
In other recent news, BioLife Solutions reported its Q1 2025 earnings, surpassing expectations with an earnings per share (EPS) of -$0.01, compared to the anticipated -$0.05. The company’s revenue reached $23.9 million, exceeding the forecasted $21.6 million, marking a 30% increase year-over-year. Analysts at H.C. Wainwright maintained a Buy rating for BioLife Solutions, with a price target of $30.00, following a discussion with the company’s management. This discussion led to an adjustment in the firm’s revenue projections for 2025, though the full-year revenue projection remains at $97.5 million. BioLife Solutions has provided full-year revenue guidance of $95.5 million to $99 million, indicating a growth of 16-20%. The company’s cell processing platform is expected to contribute significantly, with projected revenues between $86.5 million and $89 million. Despite ongoing GAAP net losses, BioLife Solutions has shown a significant improvement in reducing these losses compared to the previous year. The recent acquisition of Panthera CryoSolutions is not expected to contribute substantial revenue in 2025, but it aligns with BioLife’s strategy to enhance its biopreservation portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.